Tag Archives: Sarepta Therapeutics
Cowen & Co. Maintains Their Buy Rating on Sarepta Therapeutics (SRPT)
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of $213.00. The company’s shares closed last Monday at $124.63. According to TipRanks.com, Baral is a 5-star
Nomura Sticks to Their Buy Rating for Sarepta Therapeutics (SRPT)
In a report issued on December 23, Christopher Marai from Nomura maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $230.00. The company’s shares closed last Monday at $134.30. According to TipRanks.com, Marai
Nomura Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)
In a report issued on December 16, Christopher Marai from Nomura maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price target of $230.00. The company’s shares closed last Monday at $128.22. According to TipRanks.com, Marai
Barclays Maintains a Buy Rating on Sarepta Therapeutics (SRPT)
Barclays analyst Gena Wang maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) on December 13 and set a price target of $202.00. The company’s shares closed last Monday at $132.05. According to TipRanks.com, Wang is a 5-star
Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (NASDAQ: SRPT), Actinium Pharmaceuticals (NYSE MKT: ATNM) and Autolus Therapeutics (NASDAQ: AUTL)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report), Actinium Pharmaceuticals (ATNM – Research Report) and Autolus Therapeutics (AUTL – Research Report) with bullish sentiments.
The EVP, CFO & CBO of Sarepta Therapeutics is Exercising Options
Yesterday it was reported that the EVP, CFO & CBO of Sarepta Therapeutics (SRPT – Research Report), Sandesh Mahatme, exercised options to buy 9,754 SRPT shares at $24.73 a share, for a total transaction value of $241.2K. Following Sandesh Mahatme’s
